503A vs 503B Compounding Pharmacies: Key Differences Artixio 1 STATEMENT OF THE ALLIANCE FOR PHARMACY COMPOUNDING: UNDERSTANDING LAW AND REGULATION GOVERNING THE COMPOUNDING OF PEPTIDE PROD What is a 503B outsourcing facility, and why are so many of them uninspected by FDA? Partnership for Safe Medicines BPC 157 10mg High Purity, U.S. Made Research Peptides OROS Research The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law